Literature DB >> 24572793

Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors.

P Colella1, I Trapani1, G Cesi1, A Sommella1, A Manfredi1, A Puppo1, C Iodice1, S Rossi2, F Simonelli2, M Giunti3, M L Bacci3, A Auricchio4.   

Abstract

Gene therapy with adeno-associated viral (AAV) vectors is limited by AAV cargo capacity that prevents their application to the inherited retinal diseases (IRDs), such as Stargardt disease (STGD) or Usher syndrome type IB (USH1B), which are due to mutations in genes larger than 5 kb. Trans-splicing or hybrid dual AAV vectors have been successfully exploited to reconstitute large gene expression in the mouse retina. Here, we tested them in the large cone-enriched pig retina that closely mimics the human retina. We found that dual AAV trans-splicing and hybrid vectors transduce pig photoreceptors, the major cell targets for treatment of IRDs, to levels that were about two- to threefold lower than those obtained with a single AAV vector of normal size. This efficiency is significantly higher than that in mice, and is potentially due to the high levels of dual AAV co-transduction we observe in pigs. We also show that subretinal delivery in pigs of dual AAV trans-splicing and hybrid vectors successfully reconstitute, albeit at variable levels, the expression of the large genes ABCA4 and MYO7A mutated in STGD and USH1B, respectively. Our data support the potential of dual AAV vectors for large gene reconstitution in the cone-enriched pig retina that is a relevant preclinical model.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24572793     DOI: 10.1038/gt.2014.8

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  41 in total

1.  Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy.

Authors:  Umut Cagin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Split AAV-Mediated Gene Therapy Restores Ureagenesis in a Murine Model of Carbamoyl Phosphate Synthetase 1 Deficiency.

Authors:  Matthew Nitzahn; Gabriella Allegri; Suhail Khoja; Brian Truong; Georgios Makris; Johannes Häberle; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2020-04-17       Impact factor: 11.454

Review 3.  Gene therapy and genome surgery in the retina.

Authors:  James E DiCarlo; Vinit B Mahajan; Stephen H Tsang
Journal:  J Clin Invest       Date:  2018-06-01       Impact factor: 14.808

4.  In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery.

Authors:  Alejandro Garanto; Daniel C Chung; Lonneke Duijkers; Julio C Corral-Serrano; Muriël Messchaert; Ru Xiao; Jean Bennett; Luk H Vandenberghe; Rob W J Collin
Journal:  Hum Mol Genet       Date:  2016-04-22       Impact factor: 6.150

Review 5.  The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.

Authors:  Eric A Pierce; Jean Bennett
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

6.  Assessment of Adeno-Associated Virus Serotype Tropism in Human Retinal Explants.

Authors:  Luke A Wiley; Erin R Burnight; Emily E Kaalberg; Chunhua Jiao; Megan J Riker; Jennifer A Halder; Meagan A Luse; Ian C Han; Stephen R Russell; Elliott H Sohn; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Hum Gene Ther       Date:  2018-02-23       Impact factor: 5.695

Review 7.  Emerging Gene Therapies for Genetic Hearing Loss.

Authors:  Hena Ahmed; Olga Shubina-Oleinik; Jeffrey R Holt
Journal:  J Assoc Res Otolaryngol       Date:  2017-08-16

8.  Dual ABCA4-AAV Vector Treatment Reduces Pathogenic Retinal A2E Accumulation in a Mouse Model of Autosomal Recessive Stargardt Disease.

Authors:  Frank M Dyka; Laurie L Molday; Vince A Chiodo; Robert S Molday; William W Hauswirth
Journal:  Hum Gene Ther       Date:  2019-09-30       Impact factor: 5.695

Review 9.  Usher syndrome: Hearing loss, retinal degeneration and associated abnormalities.

Authors:  Pranav Mathur; Jun Yang
Journal:  Biochim Biophys Acta       Date:  2014-12-04

Review 10.  Promising and delivering gene therapies for vision loss.

Authors:  Livia S Carvalho; Luk H Vandenberghe
Journal:  Vision Res       Date:  2014-08-02       Impact factor: 1.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.